Search
Anavex Life Sciences Corp
AVXLAdd to Watchlist
2.760USD
+0.180+6.98%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
255.77MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+6.98%
5 Days
+5.34%
1 Month
-2.13%
6 Months
-25.00%
Year to Date
-22.47%
1 Year
-74.42%
Key Figures
2.600Open
2.785High
1.18MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.27%Turnover Ratio
2.580Prev. Close
2.570Low
2.03MTurnover
LossP/E Static
2.02P/B
0.00%Div Yield TTM
-31.08%ROA
13.99052wk High
1.21Volume Ratio
-46.38MNet Profit
92.67MShares
-0.4648EPS TTM
1.20Beta
-33.63%ROE
2.61052wk Low
8.33%Amplitude
--Gross Margin
255.77MMarket Cap
-1.85Reward/Risk
4.61%Risk Rate
TradingKey Stock Score of Anavex Life Sciences Corp
Currency: USD Updated: 2026-07-02Key Insights
Anavex Life Sciences Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 170 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Anavex Life Sciences Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Anavex Life Sciences Corp Highlights
StrengthsRisks
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Overvalued
The company’s latest PE is -5.94, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 37.30M shares, increasing 2.73% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 47.50K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.11.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
20.000
Target Price
+675.19%
Upside Space
Anavex Life Sciences Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Anavex Life Sciences Corp Info
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Ticker SymbolAVXL
CompanyAnavex Life Sciences Corp
CEOMissling (Christopher U)
Websitehttps://www.anavex.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Anavex Life Sciences Corp (AVXL)?
The current price of Anavex Life Sciences Corp (AVXL) is 2.76.
What is the symbol of Anavex Life Sciences Corp?
The ticker symbol of Anavex Life Sciences Corp is AVXL.
What is the 52-week high of Anavex Life Sciences Corp?
The 52-week high of Anavex Life Sciences Corp is 13.99.
What is the 52-week low of Anavex Life Sciences Corp?
The 52-week low of Anavex Life Sciences Corp is 2.61.
What is the market capitalization of Anavex Life Sciences Corp?
The market capitalization of Anavex Life Sciences Corp is 255.77M.
Is Anavex Life Sciences Corp (AVXL) currently rated as Buy, Hold, or Sell?
According to analysts, Anavex Life Sciences Corp (AVXL) has an overall rating of Buy, with a price target of 20.00.
What is the Earnings Per Share (EPS TTM) of Anavex Life Sciences Corp (AVXL)?
The Earnings Per Share (EPS TTM) of Anavex Life Sciences Corp (AVXL) is -0.54.